Oral XXXX as a therapeutic modality for leg @entity1066 in Beh  et's disease.

@entity1 @entity72627 @entity1423 @entity1066 @entity294 @entity5015
@entity5015 ( @entity5015 ) has been generally given only by intravascular injection. Recently, an oral @entity5015 named @entity72627 has been developed. @entity72627 is a potent inhibitor of @entity1423 as well as a strong vasodilator, and its half-life in @entity1 is extremely prolonged because it is not metabolized in the lungs. Leg ulceration is one of the cutaneous manifestations in Beh  et's disease and sometimes is very difficult to treat. In this investigation five @entity1 having Beh  et's disease with leg @entity1066 were treated with @entity72627 . All of the @entity1 had the leg @entity1066 for more than 2 months. Fifteen micrograms of @entity72627 was given initially, and the dosage was increased to 30 micrograms whenever there were no adverse effects. All the @entity1 were soon able to tolerate the drug and increased dosage. Within 2 weeks, regeneration of granulomatous tissues was observed in all cases. Furthermore, the leg @entity1066 healed within one year. Only one @entity1 developed @entity294 , but this symptom disappeared when he adjusted to the dosage. The findings strongly indicate that @entity72627 is a safe and promising drug for the treatment of leg @entity1066 in Beh  et's disease.
